InterShunt Technologies

Louisiana, United States Founded: 2015 • Age: 11 yrs
Cardiac catheters for cardiac disease treatment are developed.
Annual revenue - Latest available
Total funding $26.6M 3 rounds
Employees - Tracked headcount
Investors 4 Known backers
Products 1 Services tracked
Competitors 10 Brand Intelligence

About InterShunt Technologies

InterShunt Technologies is a company based in United States founded in 2015 by Gil Vardi. InterShunt Technologies has raised $26.55 million across 3 funding rounds from investors including Gener8tor, Solas BioVentures and Arsenal Capital Management. InterShunt Technologies offers products and services including PAS-C. InterShunt Technologies operates in a competitive market with competitors including Silk Road Medical, Lifetech Scientific Corporation, HDL Therapeutics, Supira Medical and Transvascular, among others.

  • Headquarter Louisiana, United States
  • Founders Gil Vardi
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Intershunt Technologies, Inc
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $26.55 M (USD)

    in 3 rounds

  • Latest Funding Round
    $23.42 M (USD), Series B

    Aug 09, 2024

  • Investors
    Gener8tor

    & 3 more

  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of InterShunt Technologies

InterShunt Technologies offers a comprehensive portfolio of products and services, including PAS-C.

Product name locked
Category locked
Primary

Catheter system to create atrial shunts for heart failure relief.

People of InterShunt Technologies

Headcount 1-10
Employee Profiles 3
Employee Profiles
People
Lisa Ingham
Vp, Clinical & Regulatory Affairs
People
Harlee Sorkin
CEO

Unlock access to complete

Teams

Funding Insights of InterShunt Technologies

InterShunt Technologies has successfully raised a total of $26.55M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $23.42 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in InterShunt Technologies

InterShunt Technologies has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Gener8tor, Solas BioVentures and Arsenal Capital Management.

All
Venture Fund
Investor Description Founded Year Domain Location
-
Locked Locked Locked
-
Locked Locked Locked
Venture capital and acceleration are provided to life science startups.
Locked Locked Locked
Premium access

Investor details for InterShunt Technologies

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by InterShunt Technologies

Investments
Premium access

Investment portfolio details for InterShunt Technologies

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - InterShunt Technologies

Premium access

Detailed financials for InterShunt Technologies

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Intershunt Technologies Comparisons

InterShunt Technologies Primary company
Description
Cardiac catheters for cardiac disease treatment are develope...
Location
United States
Founded Year
2015
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for InterShunt Technologies

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of InterShunt Technologies

InterShunt Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Silk Road Medical, Lifetech Scientific Corporation, HDL Therapeutics, Supira Medical and Transvascular, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Provider of neuroprotection devices for carotid artery disease
Locked Locked Locked
Interventional devices for cardiovascular and vascular diseases are developed.
Locked Locked Locked
Therapy to reverse coronary atherosclerosis is developed using patient plasma.
Locked Locked Locked
Developer of ventricular assist devices for coronary intervention and cardiogenic shock
Locked Locked Locked
A TransAccess Catheter System that is used to deliver cells to damaged portions of the heart
Locked Locked Locked
Catheter ablation treatments for atrial fibrillation are developed.
Premium access

Detailed competitors of InterShunt Technologies

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Intershunt Technologies

Premium access

Complete news archive for InterShunt Technologies

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about InterShunt Technologies

InterShunt Technologies was founded in 2015 and raised its 1st funding round 3 years after it was founded.

InterShunt Technologies is headquartered in United States. It is registered at Louisiana, United States.

Harlee Sorkin is the current CEO of InterShunt Technologies.

InterShunt Technologies is a funded company, having raised a total of $26.55M across 3 funding rounds to date.

InterShunt Technologies was founded in 2015 and is based in Louisiana, United States. Focus is placed on the medical device sector, where cardiac catheters are developed for treating cardiac conditions. Operations center on the creation of intershunt atrial septostomy catheters, which facilitate precise tissue capture, cutting, and excision from the interatrial septum. This approach aids in lowering elevated left atrial pressure. The domain intershunt.com is utilized for online presence.

InterShunt Technologies's top competitors include Silk Road Medical, Lifetech Scientific Corporation and Supira Medical.

InterShunt Technologies offers PAS-C.

InterShunt Technologies has 4 investors. Key investors include Gener8tor, Solas BioVentures, Arsenal Capital Management, and BioGenerator Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available